Skip to content

Study · Animal study (in vivo) · rat · 2012

11 results

Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat.

Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, Cao JM, Chen C

American journal of physiology. Heart and circulatory physiology27 Jul 2012Cited by 27 (Europe PMC)

PMID22842067 (opens in a new tab)DOI10.1152/ajpheart.00257.2011 (opens in a new tab)PepBankPUB-22842067
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin for 5 weeks significantly reduced cardiac fibrosis.

    In plain wordsIn rats with high blood pressure, hexarelin reduced scarring of the heart.

    Peptide
    Hexarelin
    Outcome
    DecreaseCardiac fibrosis
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment significantly reduced cardiac fibrosis in SHRs by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content and reducing mRNA and protein expression of collagen I and III in SHR hearts.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin decreased interstitial and perivascular myocardial collagen deposition.

    In plain wordsIn rats with high blood pressure, hexarelin reduced collagen build-up in the heart.

    Peptide
    Hexarelin
    Outcome
    DecreaseMyocardial collagen deposition
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment significantly reduced cardiac fibrosis in SHRs by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content and reducing mRNA and protein expression of collagen I and III in SHR hearts.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin decreased myocardial hydroxyproline content.

    In plain wordsIn rats with high blood pressure, hexarelin lowered a heart marker of collagen content.

    Peptide
    Hexarelin
    Outcome
    DecreaseMyocardial hydroxyproline content
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment significantly reduced cardiac fibrosis in SHRs by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content and reducing mRNA and protein expression of collagen I and III in SHR hearts.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In spontaneously hypertensive rats, hexarelin reduced mRNA and protein expression of collagen I and III in the heart.

    In plain wordsIn rats with high blood pressure, hexarelin lowered production of collagen types I and III in the heart.

    Peptide
    Hexarelin
    Outcome
    DecreaseCollagen I and III mRNA and protein expression
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment significantly reduced cardiac fibrosis in SHRs by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content and reducing mRNA and protein expression of collagen I and III in SHR hearts.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In spontaneously hypertensive rats, hexarelin increased matrix metalloproteinase-2 and -9 activities.

    In plain wordsIn rats with high blood pressure, hexarelin raised the activity of two collagen-degrading enzymes.

    Peptide
    Hexarelin
    Outcome
    IncreaseMMP-2 and MMP-9 activities
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment also increased matrix metalloproteinase (MMP)-2 and MMP-9 activities and decreased myocardial mRNA expression of tissue inhibitor of metalloproteinase (TIMP)-1 in SHRs.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In spontaneously hypertensive rats, hexarelin decreased myocardial mRNA expression of tissue inhibitor of metalloproteinase-1.

    In plain wordsIn rats with high blood pressure, hexarelin lowered heart expression of an inhibitor of collagen-degrading enzymes.

    Peptide
    Hexarelin
    Outcome
    DecreaseMyocardial TIMP-1 mRNA expression
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment also increased matrix metalloproteinase (MMP)-2 and MMP-9 activities and decreased myocardial mRNA expression of tissue inhibitor of metalloproteinase (TIMP)-1 in SHRs.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin significantly attenuated left ventricular hypertrophy.

    In plain wordsIn rats with high blood pressure, hexarelin reduced thickening of the heart's main pumping chamber.

    Peptide
    Hexarelin
    Outcome
    DecreaseLeft ventricular hypertrophy
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV diastolic dysfunction, and high blood pressure in SHRs.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin significantly attenuated left ventricular diastolic dysfunction.

    In plain wordsIn rats with high blood pressure, hexarelin reduced impaired relaxation of the heart's main pumping chamber.

    Peptide
    Hexarelin
    Outcome
    DecreaseLeft ventricular diastolic dysfunction
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV diastolic dysfunction, and high blood pressure in SHRs.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, hexarelin significantly attenuated high blood pressure.

    In plain wordsIn rats with high blood pressure, hexarelin lowered blood pressure.

    Peptide
    Hexarelin
    Outcome
    DecreaseBlood pressure
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV diastolic dysfunction, and high blood pressure in SHRs.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In spontaneously hypertensive rats, hexarelin treatment upregulated expression of growth hormone secretagogue receptors.

    In plain wordsIn rats with high blood pressure, hexarelin raised the expression of its own receptor.

    Peptide
    Hexarelin
    Outcome
    IncreaseGHS-R expression
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 5 weeksAs given in this study (rat).

    Source sentences

    Summary
    expression of GHS-Rs was upregulated by hexarelin treatment.
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.

Studies that did not test the peptide alone1

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 11AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Mechanism

    In spontaneously hypertensive rats, a selective GHS-R antagonist abolished hexarelin's effects on cardiac fibrosis, blood pressure and cardiac function.

    In plain wordsIn rats with high blood pressure, a receptor blocker removed hexarelin's effects on heart scarring, blood pressure and heart function.

    Peptide
    Hexarelin
    Outcome
    Not applicableEffect of GHS-R antagonist on hexarelin actions
    Study

    ratn: not reported in source

    spontaneously hypertensive rats
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    The effect of hexarelin on cardiac fibrosis, blood pressure, and cardiac function was mediated by its receptor, GHS-R, since a selective GHS-R antagonist abolished these effects
    1 context sentence
    Summary · context
    In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.